ClinicalTrials.gg

Program

Fenfluramine

Also written as “ZX008 (Fenfluramine Hydrochloride)”, “fenfluramine hydrochloride” and “fenfluramine”.

Its studies are mostly in Epilepsies, Myoclonic · Rett Syndrome · Epilepsy, Tonic-Clonic · Lennox Gastaut Syndrome, led by UCB.

Furthest: phase 3, since Feb 5, 201611 company-led studies, 2 open or runningNext primary completion: Nov 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB112 open or runningphase 3since Feb 5, 2016Feb 5, 2016Nov 8, 2027phase 3 · NCT05064878

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2016First study: phase 3 study in Epilepsies, MyoclonicFirst studyNCT02682927 · 262 enrolled · United States, Australia, Belgium and more
  2. Jun 13, 2016Phase 3 study in Epilepsies, MyoclonicNCT02823145 · 375 enrolled · United States, Australia, Belgium and more
  3. Aug 10, 2016Phase 3 study in Epilepsies, MyoclonicNCT02926898 · 87 enrolled · United States, Canada, France and more
  4. Jun 19, 2017Phase 3 study in Lennox Gastaut SyndromeNCT03355209 · 296 enrolled · United States, Australia, Belgium and more
  5. Sep 10, 2017Phase 3 study in Epilepsies, MyoclonicNCT03299842 · 5 enrolled · United States
  6. Jan 30, 2018Phase 1 study in Epilepsies, MyoclonicNCT03467113 · 9 enrolled · United States
  7. Apr 12, 2019Phase 3 study in Epilepsies, MyoclonicNCT03936777 · 412 enrolled · United States, Australia, Belgium and more
  8. Sep 22, 2021Phase 3 study in CDKL5 deficiency disorderNCT05064878 · 87 enrolled · United States, Austria, Belgium and more
  9. Oct 23, 2023Phase 3 study in Epilepsies, MyoclonicNCT06118255 · 25 enrolled · United States, Belgium, Germany and more
  10. Nov 5, 2024Phase 1 study in Healthy Study ParticipantsNCT06679413 · 22 enrolled · United States
  11. Mar 25, 2026Phase 3 study in Rett SyndromeNCT07503444 · 200 planned · United States, Belgium, France and more

Ahead

  1. Nov 8, 2027Primary completion: phase 3 study in CDKL5 deficiency disorderNCT05064878
  2. Feb 6, 2029Primary completion: phase 3 study in Rett SyndromeNCT07503444

TargetBeta

“Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07503444Rett Syndrome · United States, Belgium, France and more3RecruitingFeb 6, 2029200
NCT06679413Healthy Study Participants · United States1CompletedJun 12, 202522
NCT06118255Epilepsies, Myoclonic · United States, Belgium, Germany and more3CompletedSep 1, 202625
NCT05064878CDKL5 deficiency disorder · United States, Austria, Belgium and more3Active, not recruitingNov 8, 202787
NCT03936777Epilepsies, Myoclonic · United States, Australia, Belgium and more3CompletedMay 8, 2025412
NCT03467113Epilepsies, Myoclonic · United States1CompletedJun 24, 20209
NCT03299842Epilepsies, Myoclonic · United States3TerminatedJul 5, 20185
NCT03355209Lennox Gastaut Syndrome · United States, Australia, Belgium and more3CompletedMay 23, 2024296
NCT02926898Epilepsies, Myoclonic · United States, Canada, France and more3CompletedJun 5, 201887
NCT02823145Epilepsies, Myoclonic · United States, Australia, Belgium and more3CompletedJan 27, 2023375
NCT02682927Epilepsies, Myoclonic · United States, Australia, Belgium and more3CompletedJul 29, 2020262

How it is read

Names in the registry

  • “ZX008 (Fenfluramine Hydrochloride)”, 5 entries
  • “fenfluramine hydrochloride”, 1 entry
  • “fenfluramine”, 1 entry
  • “fenfluramine HCl”, 1 entry
  • “Fenfluramine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.